AmlodipineAntihypertensive AgentsHypertensionCalcium Channel BlockersBlood PressureHydrochlorothiazideAtenololDiureticsAngiotensin-Converting Enzyme InhibitorsTetrazolesHydralazineMethyldopaDihydropyridinesSodium Chloride Symporter InhibitorsAdrenergic beta-AntagonistsAngiotensin II Type 1 Receptor BlockersDoxazosinRats, Inbred SHRLisinoprilMinoxidilBendroflumethiazideDrug Therapy, CombinationCaptoprilNifedipineAngiotensin Receptor AntagonistsEnalaprilNordefrinBenzimidazolesChlorthalidoneBlood Pressure Monitoring, AmbulatoryGlutamyl AminopeptidaseValineClonidineDouble-Blind MethodLosartanIndapamideDiltiazemPerindoprilHypertension, RenalLabetalolTreatment OutcomeHeart RateGuanfacineRenin-Angiotensin SystemReninAzetidinecarboxylic AcidRats, Inbred WKYPropanolaminesBlood Pressure DeterminationImidazoline ReceptorsFumaratesBiphenyl CompoundsImidazolesDrug CombinationsPrazosinPatient ComplianceDose-Response Relationship, DrugSystoleKidneyAdrenergic alpha-AntagonistsHypertension, RenovascularHemodynamicsDesoxycorticosteroneKidney Failure, ChronicTime FactorsMedication AdherencePropranololProteinuriaClinical Trials as TopicDiabetic NephropathiesVasodilator AgentsProspective StudiesRisk FactorsCardiovascular DiseasesAmidesFollow-Up StudiesPhenylacetatesDelayed-Action PreparationsDiabetes Mellitus, Type 2Administration, OralBenzopyransMibefradilKidney DiseasesRamiprilRandomized Controlled Trials as TopicTrichlormethiazideCreatinineAortaArteriesCardiovascular SystemDiabetes ComplicationsCross-Over StudiesThiazidesSympathetic Nervous SystemHypertrophy, Left VentricularRisk AssessmentStrokeCilazaprilNicardipineBenzothiadiazines